Predict your next investment

HEALTHCARE | Biotechnology
singulargenomics.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Date of IPO

5/27/2021

Market Cap

0.54B

Stock Price

7.24

About Singular Genomics

Singular Genomics (NASDAQ: OMIC) develops a third-gen DNA sequencing system. The sequencing by synthesis system is based on technology licensed out of Jingyue Ju's lab at Columbia.

Singular Genomics Headquarter Location

10931 N. Torrey Pines Road #100

La Jolla, California, 92037,

United States

Latest Singular Genomics News

Singular Genomics Outlines Launch Plans for G4 Sequencer at JPM

Jan 13, 2022

Save for later Singular Genomics' new G4 sequencing-by-synthesis platform, due out in the second quarter, has the potential to challenge Illumina in the mid-throughput benchtop sequencing market. In addition to discussing the technology and its performance , CEO Drew Spaventa talked about ways the company has continued to advance the platform in his presentation at the JP Morgan Healthcare conference on Wednesday afternoon. Earlier this week, the San Diego-based company announced deals to make sample preparation and library preparation kits from Twist Bioscience, Lexogen, New England BioLabs, Watchmaker Genomics, and Dovetail Genomics compatible with its platform, taking into account the nuances of its workflow. Singular also recently partnered with the Broad Institute to integrate the Terra data platform with the G4. "This is another offering that helps us makes it easy for customers, to provide a plug-and-play solution where people can do computing, data storage, or data sharing with a seamlessly integrated cloud solution for the data flowing directly off our sequencer," Spaventa said. He also provided an update on the G4 early-access program. The fourth site, a government core lab doing microbial genome sequencing, has achieved 169 million reads per flow cell with accuracy in the range of 99.7 percent to 99.9 percent, he said, with 80 percent of the bases having a quality score above Q30. A fifth site, a commercial contract research organization, is currently using the G4 for liquid biopsy assays and a sixth site, a commercial clinical lab, is pending. Singular plans to launch several G4 consumables kits later this year. In addition to the HD-seq kit for high-accuracy rare variant detection, the company will offer XR-seq, which it describes as a product for "medium-range targeted sequencing" of regions between 500 bp and 3 kb, such as antibody VDJ regions or bacterial 16S ribosomal RNA. The product is not intended to compete with long-read sequencing, CSO and Cofounder Eli Glezer said during the Q&A session. The larger F3 flow cell, meanwhile, which will offer output of 100 Gb, is still on track to come out in the fourth quarter. The G4x4, a four-instrument configuration designed to address customers with the highest sequencing output demands, is also scheduled for launch before the end of the year. "We'll have different pricing structure for the 4x4 for customers that will really allow people to knock cost down," Spaventa said, adding that, in general, larger accounts will have access to volume discounts for all reagents. Initially, Singular will focus its direct sales efforts in the US. A second phase will target Europe and the UK before the firm plans to reach out to the rest of the world. The company is open to providing instruments on leases or reagent rentals, said Dalen Meeter, senior VP of finance. "We recognize we're a new entrant into the market and we’ll have to be flexible when it comes to customers and what they’re looking for." Still, most prospective customers are used to the traditional razor and blade business model, he said, and have been engaging with the company on those terms. While Singular is focused on bringing the G4 to market, it continues work on the PX instrument, a multiomics platform that will offer in situ sequencing and single-cell and spatial analysis capabilities. Spaventa said the company plans to launch it in 2023 but will bring up beta instruments by the middle of this year, followed by  an early-access program before the end of the year.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Singular Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singular Genomics is included in 1 Expert Collection, including Omics.

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Singular Genomics Patents

Singular Genomics has filed 15 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genetics
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/18/2020

1/18/2022

Molecular biology, DNA sequencing, Biotechnology, DNA, Genetics

Grant

Application Date

12/18/2020

Grant Date

1/18/2022

Title

Related Topics

Molecular biology, DNA sequencing, Biotechnology, DNA, Genetics

Status

Grant

Singular Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Singular Genomics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.